25613-05-2 Usage
Uses
Used in Cholestasis Studies:
Tauro-α-muricholic Acid is used as a research compound for studying cholestasis, a condition characterized by the obstruction of bile flow from the liver to the small intestine. The study of this bile acid helps researchers understand the mechanisms behind cholestasis and develop potential treatments for the condition.
Used in Pharmaceutical Industry:
Tauro-α-muricholic Acid is used as an active pharmaceutical ingredient in the development of drugs targeting liver and gallbladder disorders. Its role in the digestion and absorption of fats makes it a valuable compound for creating medications that address issues related to bile flow and fat metabolism.
Used in Diagnostic Applications:
Tauro-α-muricholic Acid is utilized as a diagnostic marker in the assessment of liver function and bile flow. Its presence and levels in the body can provide valuable information about the health of the liver and the efficiency of the bile flow, aiding in the diagnosis of various liver-related conditions.
Used in Research and Development:
Tauro-α-muricholic Acid is employed as a key compound in the research and development of new therapies and treatments for liver diseases. Its unique properties and role in bile flow make it an essential component in the development of innovative medical solutions for various hepatic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 25613-05-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,6,1 and 3 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 25613-05:
(7*2)+(6*5)+(5*6)+(4*1)+(3*3)+(2*0)+(1*5)=92
92 % 10 = 2
So 25613-05-2 is a valid CAS Registry Number.
25613-05-2Relevant academic research and scientific papers
INHIBITORS OF THE FARNESOID X RECEPTOR AND USES IN MEDICINE
-
Paragraph 0358; 0359, (2015/02/25)
Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.
Facile synthetic routes to prepare α-muricholic acid, hyocholic acid, and their taurine conjugates
Kang, Dong Wook,Luecke, Hans F.
, p. 2436 - 2440 (2013/09/24)
α-Muricholic acid was synthesized through 9 steps from chenodeoxycholic acid with 26% overall yield. Hyocholic acid was synthesized through 8 steps from the same starting material with 63% overall yield. Taurine conjugates of α-muricholic acid and hyochol
